RECOVER-ENERGIZE Platform Protocol_Appendix B (Structured Pacing (PEM))

Last updated: November 14, 2025
Sponsor: Duke University
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Covid-19

Treatment

Usual Care

Structured Pacing

Clinical Study ID

NCT06404073
Pro00112409_B
NHLBI Grant to RTI
OT2HL156812
  • Ages > 18
  • All Genders

Study Summary

This is a platform protocol designed to be flexible so that it is suitable for a range of interventions and settings within diverse health care systems and community settings with incorporation into clinical COVID-19 management programs and treatment plans if results achieve key study outcomes.

This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating interventions to address and improve exercise intolerance and post-exertional malaise (PEM) as manifestations of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC).

The focus of this protocol is to assess interventions that can improve exercise capacity, daily activities tolerance, and quality of life in patients with PASC.

Eligibility Criteria

Inclusion

• See NCT06404047 for RECOVER-ENERGIZE: Platform Protocol level inclusion and exclusion criteria which applies to this appendix

Additional Appendix B (Structured Pacing (PEM)) Level Inclusion Criteria:

  1. Participant identifies new PEM following a SARS-CoV-2 infection that has persistedfor at least 12 weeks and is still present at the time of consent

  2. Score of 2 or greater for both frequency and severity for any of the first 5questions on the Screening mDSQ-PEM AND Answer of YES to either item 7 or 8 onScreening mDSQ-PEM, and response of >14 h in item 9.

or Score of 3 or greater on any severity question(regardless) and answer of YES to either item 7 or 8 on the Screening mDSQ-PEM, and response of >14h in item 9.

Exclusion

Additional Appendix B (Structured Pacing (PEM)) Level Exclusion Criteria:

  1. Inability to attend in-person screening visit or participate in weekly visits (in-person [≥ 1] and remote)

  2. Participant was previously enrolled in Appendix A of this protocol and has NOTcompleted the full study follow-up period of Appendix A

Study Design

Total Participants: 300
Treatment Group(s): 2
Primary Treatment: Usual Care
Phase:
Study Start date:
July 17, 2024
Estimated Completion Date:
November 30, 2025

Study Description

Study interventions will be added to the platform protocol as appendices. Each appendix will leverage all elements of the platform protocol, with additional elements described in the individual appendix. Study intervention appendices may be added or removed according to adaptive design and/or emerging evidence.

The platform protocol enrolls participants who meet study eligibility criteria. After completing initial screening assessments, eligible participants are assigned to one of the study intervention appendices that are actively enrolling. Participants must meet certain criteria within a specific appendix in order to be included in that appendix. Once assigned to an appendix, eligible participants are randomized to either the study intervention group or a control group.

Connect with a study center

  • All sites listed under NCT06404047

    Durham, North Carolina 27710
    United States

    Site Not Available

  • All sites listed under NCT06404047

    Durham 4464368, North Carolina 4482348 27710
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.